An Assessment of Pharmacokinetics and Antioxidant Activity of Free Silymarin Flavonolignans in Healthy Volunteers: A Dose Escalation Study

Drug Metabolism and Disposition - Tập 41 Số 9 - Trang 1679-1685 - 2013
Hao‐Jie Zhu1,2,3, Bryan J. Brinda1,2,3, Kenneth D. Chavin1,2,3, Hilary J. Bernstein1,2,3, Kennerly S. Patrick1,2,3, John S. Markowitz1,2,3
1Department of Clinical, Social, and Administrative Sciences, University of Michigan, Ann Arbor, Michigan (H.J.Z)
2Department of Pharmacotherapy and Translational Research (H.J.Z, B.J.B, J.S.M.), Center for Pharmacogenomics (H.J.Z, B.J.B, J.S.M.), University of Florida, Gainesville, Florida
3Medical University of South Carolina, Charleston, South Carolina (K.D.C., H.J.B., K.S.P.)

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1124/jpet.109.161927

10.1016/j.jchromb.2012.06.003

10.1016/j.phymed.2012.09.004

Comporti, 2009, Oxidative stress, isoprostanes and hepatic fibrosis, Histol Histopathol, 24, 893

10.1016/j.freeradbiomed.2010.11.023

Del Rio, 2002, Selected methodologies to assess oxidative/antioxidant status in vivo: a critical review, Nutr Metab Cardiovasc Dis, 12, 343

10.1016/j.tiv.2007.11.020

10.1016/j.tiv.2010.09.001

10.2174/0929867033457115

10.1177/0091270009347475

10.1016/j.cca.2012.06.012

10.1016/S0168-8278(02)00060-0

10.1124/dmd.107.016410

10.3109/00498254.2011.573017

Javed, 2011, Reassessing bioavailability of silymarin, Altern Med Rev, 16, 239

10.1124/dmd.112.048272

Kren, 2005, Silybin and silymarin—new effects and applications, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 149, 29, 10.5507/bp.2005.002

10.1177/1534735407301825

10.1089/107555303765551633

10.1159/000312690

10.2174/092986712800493057

10.3748/wjg.v17.i18.2288

10.1055/s-0032-1315025

1985, TESS (treatment emergent symptom scale-write-in), Psychopharmacol Bull, 21, 1069

10.1016/S0021-9150(99)00257-9

Praticò, 2010, The neurobiology of isoprostanes and Alzheimer’s disease, Biochim Biophys Acta, 1801, 930, 10.1016/j.bbalip.2010.01.009

10.1016/j.chemphyslip.2003.09.012

10.1177/1740774511427064

10.1016/j.dld.2011.11.010

10.1124/dmd.111.040212

10.1124/dmd.107.019604

10.1124/dmd.32.6.587

10.1016/j.atherosclerosis.2008.06.006

Tsikas, 2003, Divergence in urinary 8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications, J Chromatogr B Analyt Technol Biomed Life Sci, 794, 237, 10.1016/S1570-0232(03)00457-4

10.1124/dmd.107.017566

Zhang, 2012, Systematic review on the association between F2-isoprostanes and cardiovascular disease, Ann Clin Biochem, 50, 108, 10.1258/acb.2012.011263

Thông tin
Thông tin xuất bản

Drug Metabolism and Disposition

Tập 41 Số 9

1679-1685

Thông tin tác giả